Features
Intraoperative OCT in Glaucoma Surgery
Enhanced visualization provided by iOCT can increase precision and confirm accurate device placement during surgical procedures.
By Syril K. Dorairaj, MD, and, Bryan C. H. Ang, MBBS, FAMS, FRCOphth, P. Connor Lentz, BS
Real-world Pearls for iDose TR Implantation
Information on initial experience complements clinical trial data.
By Savak “Sev” Teymoorian, MD, MBA
A Pro-con Discussion on Mitomycin C Use During Glaucoma Surgery
Toxicity is a major concern.
By Simon K. Law, MD, JoAnn Giaconi, MD
Web Exclusives
An Update on Novel Devices to Measure Intraocular Pressure
New options could bring innovative solutions to glaucoma monitoring.
By Alessandro A. Jammal, MD, PhD
Departments
From the Editor: Shifting Toward Interventional Glaucoma
The eye care community should prepare for a radical change.
By Nathan Radcliffe, MD
Coding: Should You Perform More Laser Trabeculoplasty?
There are far more eligible patients than those who are receiving therapy.
By Kevin J. Corcoran, COE, FNAO
Product Spotlight: The First Preservative-free Eye Drop for Glaucoma Debuts
A common treatment is now available without the drawbacks of preservatives.
By Karen Appold, contributing writer
Coding for Scleral Reinforcement Surgery
New coding practices accompany new techniques and products.
By Nathan Radcliffe, MD, Cynthia Mattox, MD
News
FDA Grants Novel Pump De Novo Status for Glaucoma Treatment
Innovative nonpharmacologic, nonsurgical device offers new hope for managing intraocular pressure in normal-tension and open-angle glaucoma patients.
Routine Optical Coherence Tomography in Optometry Boosts Glaucoma Referrals, Study Finds
Screening by optometrists could enhance early detection and prevent vision loss.
Study Identifies Variants Associated With Glaucoma in People of African Ancestry
A study in people of African ancestry identified 3 gene variants that may contribute to glaucoma.
By Conni Koury, contributing editor
Examining Bias in Published Surgical Glaucoma Clinical Trials
Researchers looked at the rates of publication bias and outcome reporting bias.
By Conni Koury, contributing editor
Positive Phase 2b Results for Bimatoprost-eluting Contact Lens
MediPrint Ophthalmics announced promising findings from the SIGHT-2 phase 2b study.
By Conni Koury, contributing editor
Landmark Noninferiority Trial Shows Benefit of Microdrops
The IOP-lowering effect with Nanodropper was noninferior to traditional drops at all time points throughout an 8-hour study, according to researchers.
By Conni Koury, contributing editor
Positive Travoprost Implant Data Presented at ASCRS
Data showed sustained reductions in IOP through 6 months.
By Conni Koury, contributing editor
Virtual Reality VF Test Accurate, Easy to Use at Home
A pilot study found that sequential unassisted, home-administered virtual reality visual field tests were reliable and accurate.
By Conni Koury, contributing editor
Sex Disparities Persist in Ophthalmology
A systematic review identified disparities at all career stages.
By Conni Koury, contributing editor
Data on IOL-based Delivery of Bimatoprost Presented at ASCRS
The IOL is designed to deliver 3 years of bimatoprost to targeted tissues.
By Conni Koury, contributing editor
FDA Grants SPA for Phase 3 Trial of Dazdotuftide
The trial will evaluate topical dazdotuftide for the treatment of noninfectious uveitis, including uveitic glaucoma.
By Conni Koury, contributing editor
IOP Lowering With Laser-guided Trabeculotomy Durable to 36 Months
All of the trabeculotomies studied were unobstructed on gonioscopic exam.
By Conni Koury, contributing editor
Travoprost Intracameral Implant Launched
Sustained drug delivery as an alternative to drops for glaucoma treatment addresses patient noncompliance.
By Conni Koury, contributing editor
Next-gen Lasers for Retina and Glaucoma Treatment Hit the Market
The Iridex 532 and Iridex 577 lasers leverage continuous-wave and patented MicroPulse Technology.
By Conni Koury, contributing editor
Novel IOP-lowering Product Targeting EVP, Distal Outflow Resistance Dosed in Phase 2
Two phase 2 randomized clinical trials are under way in patients with ocular hypertension and glaucoma.
By Conni Koury, contributing editor
AI as Good or Better Than Physicians at Managing Retina, Glaucoma Management
Research indicates that advanced AI tools could play an important role in providing decision-making support to ophthalmologists.
By Conni Koury, contributing editor
Switching to LBN Provided Additional IOP Lowering: Chart Review
A retrospective chart review found latanoprostene bunod produced approximately 25% additional IOP reduction.
By Conni Koury, contributing editor
KDB Glide Receives Expanded 510k Clearance
Five-year published data show that goniotomy with KDB Glide reduces IOP by ≥20% on average.
By Jim Gallagher, senior managing editor
AMA Adopts New Policies for Prior Authorizations
House of Delegates approves reforms to deliver greater transparency and accountability on the part of insurers.
Trial Data Show Preservative-free Benefit for Glaucoma Treatment
A bimatoprost gel without preservatives lowers IOP with fewer complications than bimatoprost preserved with BAK, study finds.
Alcon Acquires Israeli Glaucoma Company Belkin Vision
Belkin Vision is the developer of the Eagle, a laser for selective laser trabeculoplasty.
By Rochelle Nataloni, contributing writer
Travoprost Intraocular Implant Demonstrates Long-term Efficacy in Glaucoma Treatment
The implant delivers sustained therapeutic drug concentrations over 24 months.
iHealthScreen Inc Awarded US Patent for AI-Based Glaucoma Detection
The patent was secured for an AI glaucoma detection model using color fundus imaging.
Meta-analysis Suggests Benefit to Early iStent Implantation
Early trabecular bypass surgery might help stabilize glaucoma progression, the study authors found.
Social Factors Impact Glaucoma Progression
A study examined the influence of body mass index, tobacco, and alcohol consumption on glaucoma.
EssilorLuxottica to Acquire Majority Stake in Heidelberg Engineering
Purchase of an 80% stake in Heidelberg is expected to be complete later this year.
Exosome Treatment Shows Promise for Optic Nerve Recovery
Preliminary results in a nonhuman trial indicate a potential pathway for recovery of optic nerve function in glaucoma patients.
Supported Content
MIGS Middle Ground: A Case Study
With the standalone iStent infinite, glaucoma specialists no longer have to choose between endless drops and invasive surgery in managing primary open-angle glaucoma.
By Rajen U. Desai, MD
Why I Choose iStent infinite for Combined Cataract Procedures
An ophthalmologist's perspective
By Andrew A. Kao, MD
The Versatility of iStent infinite
"Traditional dogma asserts that Schlemm’s canal is no longer useful in these patients, but even patients with previously failed treatments had significant IOP lowering with a standalone iStent infinite procedure."
By J. David Stephens, MD
Retaining Patients on Drops vs Procedures
Interventional glaucoma considers procedures over drops for first-line therapy
By Mark J. Gallardo, MD